Targeted Therapies for Skin Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 7568

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Oncologic Dermatology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Elias Emergency University Hospital, Bucharest, Romania
Interests: bioactive materials; nanotechnology; targeted therapy; biologic therapy; chronic wounds; wound healing; chronic skin infections; microbial biofilms; skin cancer; melanoma
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, 060101 Bucharest, Romania
2. The Research Institute of the University of Bucharest, ICUB, 060023 Bucharest, Romania
Interests: biofilms and tolerance of biofilm-embedded cells; quorum sensing; antipathogenic strategies; human microbiota; probiotics bacterial pathogenesis; virulence factors; biofilms; antibacterial activity; antibiotic resistance; Staphylococcus aureus; Escherichia coli; Pseudomonas aeruginosa
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
1. Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, 060101 Bucharest, Romania
2. The Research Institute of the University of Bucharest, ICUB, 060023 Bucharest, Romania
3. Romanian Academy of Scientists, 050085 Bucharest, Romania
4. The Romanian Academy, 010071 Bucharest, Romania
Interests: bacterial pathogenesis; epidemiology; reservoirs; antimicrobial strategies; microbial virulence; microbial pathogenicity; virulence factors; quorum sensing; biofilms; antibacterial activity; antibiotic resistance; Staphylococcus aureus; Escherichia coli; Pseudomonas aeruginosa
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Microbiology and Immunology, Faculty of Biology, University of Bucharest, 060101 Bucharest, Romania
2. The Research Institute of the University of Bucharest, ICUB, 060023 Bucharest, Romania
Interests: microbiology; immunology; new antimicrobial agents; host-pathogen signaling; infection control; antimicrobial nanomaterials; bacterial pathogenesis; virulence factors; quorum sensing; biofilms; antibacterial activity; antibiotic resistance; Staphylococcus aureus; Escherichia coli; Pseudomonas aeruginosa; microbial molecular biology; bioactive materials; nanotechnology; nanoengineering
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Oncologic Dermatology—“Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Interests: psoriasis; inflammatory skin diseases; targeted therapy; biologic therapy; immunology

E-Mail
Guest Editor
1. Department of Microbiology II, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Cantacuzino National Military Medical Institute for Research and Development, 050096 Bucharest, Romania
Interests: infectious diseases; microbiology; chronic infections; bacteriophage; microcalorimetry; tuberculosis; blood-borne pathogens
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Oncologic Dermatology—“Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Interests: chronic wounds; skin cancer; melanoma; inflammatory skin diseases; targeted therapy; biologic therapy; immunology

E-Mail Website
Guest Editor
Department of Oncologic Dermatology—“Elias” Emergency University Hospital, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
Interests: skin cancer; melanoma; chronic wounds; inflammatory skin diseases; targeted therapy; biologic therapy; immunology

Special Issue Information

Dear Colleagues,

Over the last few years, the therapeutic landscape of cutaneous pathologies has changed tremendously. Novel diagnostic and therapeutic approaches have developed toward being based on observations resulting from artificial intelligence analysis, the study of biomarkers, and the identification of specific cellular and molecular pathogenic targets. With the emergence of ingenious topical and systemic targeted therapies, higher rates of healing and disease control in skin cancers, chronic infections, wound healing, and inflammatory and autoimmune diseases were achieved. On the other side, a wide range of adverse reactions have emerged (dermatologic or otherwise) that impact treatment outcomes and are difficult to manage, requiring experience and a multidisciplinary approach. Innovation of therapies should focus on the endpoint together with their efficiency and application in clinical practice, achieving the lowest possible cytotoxicity and incidence of adverse reactions.

As an editorial team with clinical and research experience in novel therapies (biologic therapy, Janus kinase inhibitors, immunotherapy, vaccines, drug delivery systems, nanotechnology, bioactive materials, transdermal drug delivery systems), we are pleased to invite you to contribute your recent work to this Special Issue, which aims to bring together the most innovative and interesting advances made in the targeted treatment of skin diseases.

Original research articles and review papers focusing on this intriguing field are welcome to be considered for publication in this Special Issue. We encourage you to submit your research, and this Special Issue may be printed in book format if 10 or more papers are published.

We look forward to receiving your contributions.

Dr.  Mara Mădălina Mihai
Prof. Dr. Veronica Lazǎr
Prof. Dr. Mariana-Carmen Chifiriuc
Dr. Alina-Maria Holban
Prof. Dr. Cǎlin Giurcǎneanu
Prof. Dr. Mircea Ioan Popa
Dr. Liliana Gabriela Popa
Dr. Cristina Beiu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy
  • precision medicine
  • biologic therapy
  • Janus kinase inhibitors
  • immunotherapy
  • vaccines
  • drug delivery systems
  • antimicrobials
  • nanotechnology
  • bioactive materials
  • transdermal drug delivery

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 4297 KiB  
Article
A Soft Skin Adhesive (SSA) Patch for Extended Release of Pirfenidone in Burn Wounds
by Eugene P. Chung, Jesse Q. Nguyen, Tobias Tellkamp-Schehr, Katja Goebel, Anita Ollek, Cliff Krein, Adrienne R. Wells, Eliza A. Sebastian, Anja Goebel, Svenja Niese and Kai P. Leung
Pharmaceutics 2023, 15(7), 1842; https://doi.org/10.3390/pharmaceutics15071842 - 28 Jun 2023
Viewed by 2420
Abstract
As much as half or more of deep partial-thickness burn wounds develop hypertrophic scarring and contracture. Once formed, treatments are only minimally effective. Pirfenidone (Pf), indicated for treatment of idiopathic pulmonary fibrosis, is an anti-inflammatory and anti-fibrotic small molecule that potentially can be [...] Read more.
As much as half or more of deep partial-thickness burn wounds develop hypertrophic scarring and contracture. Once formed, treatments are only minimally effective. Pirfenidone (Pf), indicated for treatment of idiopathic pulmonary fibrosis, is an anti-inflammatory and anti-fibrotic small molecule that potentially can be repurposed as a preventative against scarring in burn wounds. We present a drug-in-matrix patch with a soft skin adhesive (SSA) wound-contacting layer for multi-day drug delivery of Pf into burn wounds at the point of injury. Our patch construction consists of an SSA adhesive layer (Liveo™ MG7-9850, Dupont, Wilmington, DE, USA) for wound fixation, an acrylic co-polymer drug matrix (DURO-TAK 87-2852, Henkel, Düsseldorf, Germany) as the drug (Pf) reservoir, and an outermost protective polyurethane backing. By employing a drug-in-matrix patch design, Pf can be loaded as high as 2 mg/cm2. Compared to the acrylic co-polymer adhesive patch preparations and commercial films, adding an SSA layer markedly reduces skin stripping observed under scanning electron microscopy (SEM). Moreover, the addition of varying SSA thicknesses did not interfere with the in vitro release kinetics or drug permeation in ex vivo porcine skin. The Pf patch can be easily applied onto and removed from deep partial-thickness burn wounds on Duroc pigs. Continuous multi-day dosing of Pf by the patches (>200 μg/cm2/day) reduced proinflammatory biomarkers in porcine burn wounds. Pf patches produced by the manual laboratory-scale process showed excellent stability, maintaining intact physical patch properties and in vitro biological activity for up to one year under long-term (25 °C at 60% RH) and 6 months under accelerated (40 °C at 75% RH) test conditions. To manufacture our wound safe-and-extended-release patch, we present scale-up processes using a machine-driven automated roll-to-roll pilot scale coater. Full article
(This article belongs to the Special Issue Targeted Therapies for Skin Diseases)
Show Figures

Figure 1

Review

Jump to: Research

21 pages, 3750 KiB  
Review
An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
by Olguța Anca Orzan, Cristian George Țieranu, Andrei Ovidiu Olteanu, Alexandra Maria Dorobanțu, Anca Cojocaru, Mara Mădălina Mihai, Liliana Gabriela Popa, Ana Maria Gheorghiu, Călin Giurcăneanu and Ana Ion
Pharmaceutics 2023, 15(8), 2171; https://doi.org/10.3390/pharmaceutics15082171 - 21 Aug 2023
Cited by 3 | Viewed by 1733
Abstract
Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2–3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, resulting in the production of proinflammatory cytokines such as tumor necrosis factor [...] Read more.
Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2–3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, resulting in the production of proinflammatory cytokines such as tumor necrosis factor alpha, interleukin 17, interleukin 23, interleukin 22, and interleukin 1β. An in-depth understanding of the pathophysiology of psoriasis led to significant advances in the development of safe and efficient novel therapeutic options, with four classes of biologic therapy being approved for the management of moderate to severe psoriasis: tumor necrosis factor alpha inhibitors, interleukin 23 inhibitors, anti-interleukin 12/23 agents, anti-interleukin 17 agents, as well as small-molecule inhibitors, such as apremilast. Psoriasis is associated with comorbid conditions, namely psoriatic arthritis, cardiovascular disease, metabolic syndrome, psychiatric disorders, malignancy, as well as inflammatory bowel disease. For patients affected by both psoriasis and inflammatory bowel disease, there is a strong recommendation to avoid IL-17 inhibitors since they may play a part in the exacerbation of the gastrointestinal disease. Our aim was to perform a thorough literature review regarding the development of inflammatory bowel disease lesions in psoriasis patients treated with IL-17 inhibitors, along with a case presentation to emphasize the need for close follow-up of these patients. Full article
(This article belongs to the Special Issue Targeted Therapies for Skin Diseases)
Show Figures

Figure 1

19 pages, 709 KiB  
Review
Antimicrobial Biomaterials for Chronic Wound Care
by Adrian Miron, Calin Giurcaneanu, Mara Madalina Mihai, Cristina Beiu, Vlad Mihai Voiculescu, Marius Nicolae Popescu, Elena Soare and Liliana Gabriela Popa
Pharmaceutics 2023, 15(6), 1606; https://doi.org/10.3390/pharmaceutics15061606 - 28 May 2023
Cited by 3 | Viewed by 2394
Abstract
Chronic wounds encompass a myriad of lesions, including venous and arterial leg ulcers, diabetic foot ulcers (DFUs), pressure ulcers, non-healing surgical wounds and others. Despite the etiological differences, chronic wounds share several features at a molecular level. The wound bed is a convenient [...] Read more.
Chronic wounds encompass a myriad of lesions, including venous and arterial leg ulcers, diabetic foot ulcers (DFUs), pressure ulcers, non-healing surgical wounds and others. Despite the etiological differences, chronic wounds share several features at a molecular level. The wound bed is a convenient environment for microbial adherence, colonization and infection, with the initiation of a complex host–microbiome interplay. Chronic wound infections with mono- or poly-microbial biofilms are frequent and their management is challenging due to tolerance and resistance to antimicrobial therapy (systemic antibiotic or antifungal therapy or antiseptic topicals) and to the host’s immune defense mechanisms. The ideal dressing should maintain moisture, allow water and gas permeability, absorb wound exudates, protect against bacteria and other infectious agents, be biocompatible, be non-allergenic, be non-toxic and biodegradable, be easy to use and remove and, last but not least, it should be cost-efficient. Although many wound dressings possess intrinsic antimicrobial properties acting as a barrier to pathogen invasion, adding anti-infectious targeted agents to the wound dressing may increase their efficiency. Antimicrobial biomaterials may represent a potential substitute for systemic treatment of chronic wound infections. In this review, we aim to describe the available types of antimicrobial biomaterials for chronic wound care and discuss the host response and the spectrum of pathophysiologic changes resulting from the contact between biomaterials and host tissues. Full article
(This article belongs to the Special Issue Targeted Therapies for Skin Diseases)
Show Figures

Figure 1

Back to TopTop